Literature DB >> 21523334

Emerging therapeutic targets for soft tissue sarcoma.

Jason L Smith1, Richard F Riedel.   

Abstract

Soft tissue sarcomas (STS) are malignancies of mesenchymal origin that represent approximately 1% of cancers in adults. Systematic research into the treatment of STS is challenging given its rarity and disease heterogeneity. Despite the ability to histologically subtype STS, only recently has our approach to therapy begun to differentiate along these lines. The purpose of this review is to highlight emerging therapeutic targets and therapies that hold the potential to add to the current state of systemic treatment for STS.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21523334     DOI： 10.1007/s11912-011-0175-y

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  77 in total

1.  Dramatic improvement of inoperable angiosarcoma with combination paclitaxel and bevacizumab chemotherapy.

Authors:  Christopher K Fuller; John A Charlson; Steven K Dankle; Thomas J Russell
Journal:  J Am Acad Dermatol       Date:  2010-10       Impact factor: 11.527

2.  Hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) are potential targets in uterine leiomyosarcoma.

Authors:  Keiichiro Nakamura; Fernando Abarzua; Atsushi Hongo; Junichi Kodama; Yasutomo Nasu; Hiromi Kumon; Yuji Hiramatsu
Journal:  Int J Oncol       Date:  2010-09       Impact factor: 5.650

3.  Partial response to bevacizumab of an extensive cutaneous angiosarcoma of the face.

Authors:  A Rosen; S Thimon; D Ternant; M C Machet; G Paintaud; L Machet
Journal:  Br J Dermatol       Date:  2010-04-12       Impact factor: 9.302

4.  A small-molecule inhibitor of MDMX activates p53 and induces apoptosis.

Authors:  Hongbo Wang; Xujun Ma; Shumei Ren; John K Buolamwini; Chunhong Yan
Journal:  Mol Cancer Ther       Date:  2010-11-12       Impact factor: 6.261

Review 5.  Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor.

Authors:  Min S Park; Vinod Ravi; Dejka M Araujo
Journal:  Curr Opin Oncol       Date:  2010-07       Impact factor: 3.645

6.  Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

Authors:  Elise A Olsen; Youn H Kim; Timothy M Kuzel; Theresa R Pacheco; Francine M Foss; Sareeta Parker; Stanley R Frankel; Cong Chen; Justin L Ricker; Jean Marie Arduino; Madeleine Duvic
Journal:  J Clin Oncol       Date:  2007-06-18       Impact factor: 44.544

7.  Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

Authors:  Robert G Maki; David R D'Adamo; Mary L Keohan; Michael Saulle; Scott M Schuetze; Samir D Undevia; Michael B Livingston; Matthew M Cooney; Martee L Hensley; Monica M Mita; Chris H Takimoto; Andrew S Kraft; Anthony D Elias; Bruce Brockstein; Nathalie E Blachère; Mark A Edgar; Lawrence H Schwartz; Li-Xuan Qin; Cristina R Antonescu; Gary K Schwartz
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

8.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.

Authors:  S W Morris; M N Kirstein; M B Valentine; K G Dittmer; D N Shapiro; D L Saltman; A T Look
Journal:  Science       Date:  1994-03-04       Impact factor: 47.728

9.  Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.

Authors:  George D Demetri; Sant P Chawla; Margaret von Mehren; Paul Ritch; Laurence H Baker; Jean Y Blay; Kenneth R Hande; Mary L Keohan; Brian L Samuels; Scott Schuetze; Claudia Lebedinsky; Yusri A Elsayed; Miguel A Izquierdo; Javier Gómez; Youn C Park; Axel Le Cesne
Journal:  J Clin Oncol       Date:  2009-08-03       Impact factor: 44.544

10.  Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).

Authors:  Stefan Sleijfer; Monia Ouali; Martine van Glabbeke; Anders Krarup-Hansen; Sjoerd Rodenhuis; Axel Le Cesne; Pancras C W Hogendoorn; Jaap Verweij; Jean-Yves Blay
Journal:  Eur J Cancer       Date:  2010-01       Impact factor: 9.162
View more
  1 in total

1.  Targeted polytherapy in small cell sarcoma and its association with doxorubicin.

Authors:  S N Dumont; D Yang; A G Dumont; D Reynoso; J-Y Blay; J C Trent
Journal:  Mol Oncol       Date:  2014-06-10       Impact factor: 6.603
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.